Xiangdong Zhou

Meta-learning has effectively addressed the limit of deep learning fault diagnosis models that demands a large number of samples. However, existing meta-learning models lack the capacity of feature reuse and task adaptability. To address the cross-domain fault diagnosis tasks with small samples, the feature reuse capability and task adaptability of existing meta-learning models need further improvements. To achieve this goal, this paper introduces a new approach built upon the task-supervised Almost No Inner Loop (ANIL). The proposed approach adopts a residual network to optimize the backbone structure of the inner loop, enhancing the feature reuse capability of the meta-learning in the unknown domain. An auxiliary term is introduced to define a supervised task-adaptive loss function, further updating the weight parameters of the inner loop meta-learner by monitoring the states of all meta-diagnostic tasks. The proposed method is used to analyze vibration signals from various bearings. The results demonstrate its superiority over traditional meta-learning methods in multiple sets of cross-domain fault diagnosis tasks with small samples.

PURPOSE Epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR -mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum–based chemotherapy with or without pembrolizumab for TKI-resistant, EGFR -mutant, metastatic nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837 ). METHODS Adults with pathologically confirmed stage IV nonsquamous NSCLC, documented DEL19 or L858R EGFR mutation, and progression after EGFR-TKI treatment were randomly assigned 1:1 to 35 cycles of pembrolizumab 200 mg or placebo once every 3 weeks plus four cycles of pemetrexed and carboplatin or cisplatin once every 3 weeks and then maintenance pemetrexed. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Final PFS testing was completed at the second interim analysis (IA2; data cutoff, December 3, 2021); OS was tested at final analysis (FA; data cutoff, January 17, 2023). Efficacy boundaries were one-sided P = .0117 for PFS and OS. RESULTS Four hundred ninety-two patients were randomly assigned to pembrolizumab plus chemotherapy (n = 245) or placebo plus chemotherapy (n = 247). At IA2, the median PFS was 5.6 months for pembrolizumab plus chemotherapy versus 5.5 months for placebo plus chemotherapy (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.97]; P = .0122). At FA, the median OS was 15.9 versus 14.7 months, respectively (HR, 0.84 [95% CI, 0.69 to 1.02]; P = .0362). Grade ≥3 treatment-related adverse events occurred in 43.7% of pembrolizumab plus chemotherapy recipients versus 38.6% of placebo plus chemotherapy recipients. CONCLUSION Addition of pembrolizumab to chemotherapy in patients with TKI-resistant, EGFR -mutant, metastatic nonsquamous NSCLC did not significantly prolong PFS or OS versus placebo plus chemotherapy in KEYNOTE-789.

Abstract The nanoencapsulation of hydrophobic compounds by miniemulsion polymerization, a convenient one‐step encapsulation technique for nanocapsules, was investigated in terms of the thermodynamics and kinetics. The encapsulation was achieved by polymerization inducing phase separation within minidroplets dispersed in an aqueous phase. Thermodynamic factors (the level and type of surfactant, the level of the hydrophilic comonomer, and the monomer/paraffin ratio), kinetic factors (the level of the crosslinking agent or chain‐transfer agent), and nucleation modes were all found to have a great influence on the latex morphology. Specifically, for a styrene/paraffin system, there were optimum levels of sodium dodecyl sulfate (1.0 wt %), the hydrophilic comonomer (1.0 wt % methyl acrylate acid), and the chain‐transfer agent (0.2 wt % n ‐dodecanethiol) for obtaining well‐defined nanocapsules of paraffin with a styrene/paraffin ratio of 1:1. When the styrene/paraffin ratio was reduced, however, it was more difficult to achieve a fully encapsulated particle morphology. Homogeneous nucleation could compete with encapsulation, and this resulted in a pure polymer particle and a half‐moon morphology. Conditions were also found under which complete encapsulation could be observed with a water‐soluble initiator (potassium persulfate), contrary to certain reports. Replacing potassium persulfate with an oil‐soluble initiator (2,2‐azobisisobutyronitrile) had little influence on the morphology under those conditions. © 2004 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 42: 2145–2154, 2004